查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1376086

心血管臨床試驗市場規模、佔有率和趨勢分析報告：2023-2030 年按階段、研究設計、適應症、地區和細分市場分類的趨勢

Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, & Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10個工作天內

價格

心血管臨床試驗市場成長與趨勢：

根據 Grand View Research, Inc. Masu 的最新報告，預計到 2030 年，全球心血管臨床試驗市場規模將達到 84.1 億美元，2023 年至 2030 年年複合成長率為 6.0%。

市場成長主要是由於心臟衰竭、中風和冠狀動脈疾病等心血管疾病的盛行率不斷增加。此外，包括個人化醫療和基因組學在內的醫學研究的不斷進步，正在推動臨床試驗研究新策略和治療方法的需求。此外，臨床研究的技術創新，例如採用虛擬臨床試驗和遠端監控臨床試驗患者，正在促進更具成本效益和更有效率的臨床試驗管理，以支持市場成長。

市場分散，多家公司擁有相似的技術力和加工能力。多家委外研發機構已進入心血管臨床試驗領域。此外，這些公司正在對新型化合物進行實驗，並專注於心血管治療療法的創新。這些公司專注於與生物製藥公司建立夥伴關係和合作，以提高其在市場上的影響力。例如，2023 年 8 月，臨床研究組織 Dr. Vince Clinical Research (DVCR) 宣布與 Clario 建立策略夥伴關係，在臨床試驗中提供心臟評估。

此外，臨床試驗的全球化也是支持市場成長的關鍵因素。例如，根據Clinical Trial Arena 2022年5月的數據，西方商業公司參與在中國進行的臨床試驗已從2010年的年度約100家逐漸增加到2021年的約350家。因此，這是預測期內支持市場成長的主要因素之一。

COVID-19 大流行對市場產生了負面影響。由於旅行限制，COVID-19 大流行的早期階段嚴重影響了臨床試驗，包括心血管適應症的試驗。然而，透過採用虛擬臨床試驗和分散臨床試驗等新的測試方法，市場出現了反彈。

心血管臨床試驗市場報告亮點

  • 依階段分類，2022年第四期業務佔比最大，為34.3%。此細分市場的推動因素是對新型療法的需求不斷成長，以及涵蓋真實世界臨床資料以加強對上市後監測過程的評估。
  • 根據研究設計，2022 年介入細分市場所佔佔比最大，為 64.8%。這種高細分市場佔有率的主要原因是受控介入臨床試驗中心血管藥物的研發管線不斷增加。
  • 有跡象表明，由於全球患病率上升以及對創新中風治療的需求不斷成長，中風領域在分析期間預計將以 6.9% 的年複合成長率成長。
  • 亞太地區預計在預測期內年複合成長率為 6.8%。高成長主要是由於越來越多的西方製藥公司將其製造活動外包給中國和印度等新興經濟體。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 臨床試驗市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 心血管臨床試驗市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章 臨床試驗市場：階段估計與趨勢分析

  • 心血管臨床試驗市場，依階段：細分儀表板
  • 心血管臨床試驗市場（按階段）：變異分析

第5章 臨床試驗市場：研究設計估算與趨勢分析

  • 心血管臨床試驗市場，依研究設計：細分儀表板
  • 心血管臨床試驗市場，依研究設計：變異分析

第6章 臨床試驗市場：適應症估計與估計/趨勢分析

  • 心血管臨床試驗市場，依適應症：細分儀表板
  • 心血管臨床試驗市場，依適應症：變異分析

第7章 臨床試驗市場：區域估計與趨勢分析

  • 2022 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 市場參與企業分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2022 年公司市場佔有率分析
  • 公司簡介
    • IQVIA Inc
    • ICON plc
    • SGS SA
    • Eli Lilly and Company
    • PPD Inc
    • Syneos Health
    • Caidya
    • Worldwide Clinical Trials
    • Vial
    • Veeda Clinical Research
    • Medpace, Inc.
Product Code: GVR-4-68040-135-0

Cardiovascular Clinical Trials Market Growth & Trends:

The global cardiovascular clinical trials market size is expected to reach USD 8.41 billion by 2030, registering a CAGR of 6.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market's growth is majorly due to the increasing prevalence of cardiovascular diseases such as heart failure, stroke, and coronary artery diseases. Furthermore, the persistent advancements in medical research, including personalized medicine and genomics, fuel the need for clinical trials to investigate novel strategies and therapies. In addition, technological innovations in clinical research, such as the adoption of virtual clinical trials and remote monitoring of clinical trial patients, facilitate more cost-effective and efficient clinical trial management, thus supporting the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. Several contract research organizations are penetrating the space of cardiovascular clinical trials. Moreover, these companies are focusing on innovating cardiovascular treatment therapies with experimentation over novel compounds. These players focus on partnerships and collaborations with bio-pharmaceutical companies to enhance their market presence. For instance, in August 2023, Dr. Vince Clinical Research (DVCR); a clinical research organization, announced a strategic alliance with Clario for delivering cardiac assessments in clinical trials.

Furthermore, the globalization of clinical trials is another significant factor supporting the market's growth. For instance, in May 2022, according to the clinical trials arena, the involvement of Western commercial companies in trials run in China has grown gradually from around 100 trials per year in 2010 to around 350 trials in 2021. Hence, this is one of the primary factors supporting the market growth during the forecast period.

The COVID-19 pandemic negatively impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving cardiovascular indications. However, the market recovered by adopting novel trial methods such as virtual and decentralized clinical trials.

Cardiovascular Clinical Trials Market Report Highlights:

  • Based on phase, the Phase IV segment accounted for the largest share of 34.3% in 2022. The segment is driven by the growing demand for novel therapeutics and the incorporation of real-world data for enhanced assessment of the post-marketing surveillance process
  • Based on the study design, the interventional segment accounted for the largest share of 64.8% in 2022. High segment shares are majorly due to the growing pipeline of cardiovascular therapeutics under controlled interventional clinical trials
  • Based on indication, the stroke segment is anticipated to witness the highest CAGR of 6.9% across the analysis timeframe due to the increasing prevalence rate of the condition globally and the surge in the need for innovative stroke treatment therapies
  • Asia Pacific is anticipated to witness the highest CAGR of 6.8% during the forecast time frame. High growth is primarily due to the increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Phase
    • 1.1.3. Study Design
    • 1.1.4. Indication
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cardiovascular Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising burden of cardiovascular diseases globally
      • 3.2.1.2. Globalization of clinical trials
      • 3.2.1.3. Increasing R&D expenditure towards clinical trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rigorous approval standards set by regulatory bodies
      • 3.2.2.2. Patient recruitment and retention challenges
  • 3.3. Cardiovascular Clinical Trials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cardiovascular Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Cardiovascular Clinical Trials Market, By Phase: Segment Dashboard
  • 4.2. Cardiovascular Clinical Trials Market, By Phase: Movement Analysis
  • 4.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 4.3.1. Phase I
      • 4.3.1.1. Phase I Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.2. Phase II
      • 4.3.2.1. Phase II Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.3. Phase III
      • 4.3.3.1. Phase III Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.4. Phase IV
      • 4.3.4.1. Phase IV Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 5. Cardiovascular Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Cardiovascular Clinical Trials Market, By Study Design: Segment Dashboard
  • 5.2. Cardiovascular Clinical Trials Market, By Study Design: Movement Analysis
  • 5.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Study Design, 2018 - 2030
    • 5.3.1. Interventional
      • 5.3.1.1. Interventional Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.2. Observational
      • 5.3.2.1. Observational Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.3. Expanded Access
      • 5.3.3.1. Expanded Access Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 6. Cardiovascular Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Cardiovascular Clinical Trials Market, By Indication: Segment Dashboard
  • 6.2. Cardiovascular Clinical Trials Market, By Indication: Movement Analysis
  • 6.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 6.3.1. Acute Coronary Syndrome
      • 6.3.1.1. Acute Coronary Syndrome Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.2. Coronary Artery Disease
      • 6.3.2.1. Coronary Artery Disease Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.3. Ischemic Heart Disease
      • 6.3.3.1. Ischemic Heart Disease Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.4. Pulmonary Arterial Hypertension
      • 6.3.4.1. Pulmonary Arterial Hypertension Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.5. Stroke
      • 6.3.5.1. Stroke Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.6. Cardiac Arrhythmias
      • 6.3.6.1. Cardiac Arrhythmias Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.7. Heart Failure
      • 6.3.7.1. Heart Failure Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.8. Others
      • 6.3.8.1. Others Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 7. Cardiovascular Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2022 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2022
  • 8.2. Company Profiles
    • 8.2.1. IQVIA Inc
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. ICON plc
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. SGS SA
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Eli Lilly and Company
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. PPD Inc
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Syneos Health
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. Caidya
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Worldwide Clinical Trials
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. Vial
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Veeda Clinical Research
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives
    • 8.2.11. Medpace, Inc.
      • 8.2.11.1. Company Overview
      • 8.2.11.2. Financial Performance
      • 8.2.11.3. Service Benchmarking
      • 8.2.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 North America Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 6 North America Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 7 U.S. Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 8 U.S. Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 9 U.S. Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 10 Canada Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 11 Canada Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 12 Canada Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 13 Europe Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 14 Europe Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 15 Europe Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 16 Europe Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 17 UK Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 18 UK Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 19 UK Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 20 Germany Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 21 Germany Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 22 Germany Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 23 France Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 24 France Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 25 France Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 26 Italy Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 27 Italy Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Italy Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 29 Spain Cardiovascular Clinical Trials market, by Study Design type, 2018 - 2030 (USD Million)
  • Table 30 Spain Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 31 Spain Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 32 Denmark Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 33 Denmark Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 34 Denmark Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 Sweden Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 36 Sweden Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 37 Sweden Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 38 Norway Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 39 Norway Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Norway Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 45 China Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 46 China Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 47 China Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 48 Japan Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 Japan Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 50 Japan Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 51 India Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 52 India Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 53 India Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 54 Australia Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 55 Australia Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 56 Australia Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 57 South Korea Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 58 South Korea Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 59 South Korea Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 60 Thailand Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 61 Thailand Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 62 Thailand Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 63 Latin America Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 64 Latin America Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 65 Latin America Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Latin America Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 67 Brazil Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 68 Brazil Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Brazil Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 70 Mexico Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 71 Mexico Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Mexico Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 73 Argentina Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 74 Argentina Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 75 Argentina Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa Cardiovascular Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 79 Middle East and Africa Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 80 South Africa Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 81 South Africa Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 82 South Africa Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 86 UAE Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 87 UAE Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 88 UAE Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Cardiovascular Clinical Trials market, by Study Design, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Cardiovascular Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Cardiovascular Clinical Trials market, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary Interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Cardiovascular Clinical Trials Market Segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's Five Forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Cardiovascular Clinical Trials Market Phase outlook: Segment dashboard
  • Fig. 26 Cardiovascular Clinical Trials: Phase movement analysis
  • Fig. 27 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 28 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 29 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 30 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 31 Cardiovascular Clinical Trials Market Study Design Outlook: Segment dashboard
  • Fig. 32 Cardiovascular Clinical Trials: Study Design type movement analysis
  • Fig. 33 Interventional market, 2018 - 2030 (USD Million)
  • Fig. 34 Observational market, 2018 - 2030 (USD Million)
  • Fig. 35 Expanded Access market, 2018 - 2030 (USD Million)
  • Fig. 36 Cardiovascular Clinical Trials market Indication outlook: Segment dashboard
  • Fig. 37 Cardiovascular Clinical Trials market: Indication movement analysis
  • Fig. 38 Acute Coronary Syndrome market, 2018 - 2030 (USD Million)
  • Fig. 39 Coronary Artery Disease market, 2018 - 2030 (USD Million)
  • Fig. 40 Ischemic Heart Disease market, 2018 - 2030 (USD Million)
  • Fig. 41 Pulmonary Arterial Hypertension market, 2018 - 2030 (USD Million)
  • Fig. 42 Stroke market, 2018 - 2030 (USD Million)
  • Fig. 43 Cardiac Arrhythmias market, 2018 - 2030 (USD Million)
  • Fig. 44 Heart Failure market, 2018 - 2030 (USD Million)
  • Fig. 45 Others market, 2018 - 2030 (USD Million)
  • Fig. 46 Regional marketplace: Segment dashboard
  • Fig. 47 Regional outlook, 2022 & 2030
  • Fig. 48 North America market, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 50 Canada market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe market, 2018 - 2030 (USD Million)
  • Fig. 52 Germany market, 2018 - 2030 (USD Million)
  • Fig. 53 UK market, 2018 - 2030 (USD Million)
  • Fig. 54 France market, 2018 - 2030 (USD Million)
  • Fig. 55 Italy market, 2018 - 2030 (USD Million)
  • Fig. 56 Spain market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark market, 2018 - 2030(USD Million)
  • Fig. 58 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 59 Norway market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 61 China market, 2018 - 2030 (USD Million)
  • Fig. 62 Japan market, 2018 - 2030 (USD Million)
  • Fig. 63 India market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia market, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 71 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait market, 2018 - 2030 (USD Million)